Skip to content

Comparison of remimazolam-propofol versus midazolam-propofol for sedation in young children undergoing magnetic resonance imaging: a randomized controlled trial

Comparison of remimazolam-propofol versus midazolam-propofol for sedation in young children undergoing magnetic resonance imaging: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119564
Enrollment
Unknown
Registered
2026-02-28
Start date
2026-02-28
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Group A:Intravenous remimazolam 0.3 mg/kg followed by propofol 2 mg/kg
Group B:Intravenous midazolam 0.15 mg/kg followed by propofol 2 mg/kg

Sponsors

Shanghai Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1.aged 1-6 years, gender not restricted; 2.Body weight 8-20 kg; 3.ASA score I or II; 4.scheduled for an MRI examination under deep sedation; 5.Informed consent signed by parents/guardians.

Exclusion criteria

Exclusion criteria: 1.Diagnostic imaging expected to last longer than 1 hour; 2.Difficult airways; 3.Acute respiratory tract infection; 4.Contraindications to any of the investigated agents; 5.Abnormal liver or kidney function; 6.Neurological diseases; 7.Mental or psychological disorders; 8.A body mass index (BMI) above 30 kg/m^²

Design outcomes

Primary

MeasureTime frame
The first-attempt sedation success rate;The overall sedation time;

Secondary

MeasureTime frame
Sedation onset time;Awakening time;Recovery time;Incidence of adverse events;

Countries

China

Contacts

Public ContactYing Sun

Department of Anesthesiology, Shanghai Children's Medical Center

yingsun821@163.com+86 136 2173 8118

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026